Johnson & Johnson (JNJ)
J&J's Spravato momentum points to commercial viability of psychedelics for mental health, analysts say
Another quarter of consistent growth for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato bodes well for other psychedelics, analysts at Jefferies believe. They see consistent quarter-over-quarter Spravato sales growth supporting the notion psychedelics can become commercially viable in mental health.
Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q1 2025 Earnings Conference Call April 15, 2025 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Executive Officer John Reed - EVP, Innovative Medicine, R&D Joseph Wolk - EVP, Chief Financial Officer Jennifer Taubert - EVP, Worldwide Chairman, Innovative Medicine Tim Schmid - EVP, Worldwide Chairman, MedTech Conference Call Participants Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan Asad Haider - Goldman Sachs Danielle Antalffy - UBS Terence Flynn - Morgan Stanley Joanne Wuensch - Citibank Vamil Divan - Guggenheim Securities Matt Miksic - Barclays Tim Anderson - Bank of America Operator Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference.
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.
Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves
Johnson & Johnson's Q1 2025 earnings show a 2.4% sales increase and a significant EPS rise, despite litigation charges impacting GAAP figures. The MedTech division grew 4.1%, driven by acquisitions, while Pharmaceuticals saw a 4.2% increase, despite challenges like Stelara's patent expiry. JNJ raised its full-year revenue guidance and increased its dividend, reflecting confidence in long-term growth despite short-term litigation and tariff uncertainties.
Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson tops Q1 expectations, lifts 2025 sales outlook
Johnson & Johnson (NYSE:JNJ) reported its first quarter earnings, with both revenue and profit beating Wall Street expectations driven by strong sales in its oncology portfolio, especially the multiple myeloma drug Darzalex. Revenue was up 2.4% year-over-year at $21.89 billion, ahead of estimates of $21.56 billion.
Johnson & Johnson raised its sales outlook, even with tariff costs included
Johnson & Johnson beat Wall Street's expectations for first-quarter profit and revenue on Tuesday, as strong growth in the U.S. offset weakness internationally.
Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook
Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.
J&J Increases Outlook After Beating 1Q Expectations
Johnson & Johnson now expects sales of up to $91.8 billion in 2025, compared with a prior view of up to $90 billion.
Johnson & Johnson: Fairly Valued, But Recession-Resilient
Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate growth in sales and earnings, with notable performance in the oncology and cardiovascular segments. Analysts expect low-to-mid single-digit growth for Johnson & Johnson, with a focus on operational efficiency and share buybacks to boost the bottom line.
Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Pharma tariffs unlikely to hit earnings before 2026, analysts say
Potential tariffs on pharmaceuticals under the Trump administration would take more time to have an impact on the sector than investors may realize, analysts at Bank of America believe. US president Donald Trump said on Tuesday that the country would soon be announcing a “major tariff” on pharmaceuticals with the aim of onshoring drug manufacturing.
